Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese casesShort Communication Published on 2024-06-272024-09-05 Journal: Journal of clinical and experimental hematopathology : JCEH [Category] update2024, [키워드] chronic lymphocytic leukemia Japanese rituximab Small lymphocytic lymphoma venetoclax [DOI] 10.3960/jslrt.24014 PMC 바로가기 [Article Type] Short Communication
Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients혈액학적 환자에서 mRNA SARS-CoV-2 백신으로의 혈청전환Article Published on 2022-05-122022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] 95% CI acute leukemia acute myeloid leukemia Algorithm Analysis Anti-spike BNT162b2 chronic lymphocytic leukemia CLL COVID-19 Diagnosis disorders hematologic IgG IgG level IgG levels indolent Italy lack leukemia Lymphocytic leukemia lymphoma Moderna monoclonal antibodies mRNA mRNA vaccination mRNA-1273 Multiple myeloma multivariable analysis myelofibrosis myeloproliferative disorders myeloproliferative disorders. Neoplasms normal range Patient patients Pfizer Pfizer-BioNTech predict predictor prospective cohort study receiving response risk factor ruxolitinib SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines Seroconversion seroconverted simple algorithm single center small molecule Small molecules therapy treated Treatment vaccine administration vaccine dose venetoclax [DOI] 10.3389/fimmu.2022.852158 PMC 바로가기 [Article Type] Article
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination표준 2회 접종에 실패한 CLL 환자에서 3차 BNT162b2 mRNA COVID-19 백신 접종의 효능Clinical Trial Published on 2022-02-032022-09-12 Journal: Blood [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI acute respiratory syndrome administration Analysis anti-CD20 Anti-CD20 antibody anti-CD20 therapy antibody Antibody Response antibody response rate BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 mRNA vaccine BTK CLL coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose evaluated humoral immunoglobulin A independent variable inhibitor lack leukemia lymphoma Patient regimen Registered response rate SARS-CoV-2 serum the antibody response therapy treated treated patient Treatment treatment-naïve patient Trial tyrosine vaccination Vaccine venetoclax were measured [DOI] 10.1182/blood.2021014085 PMC 바로가기 [Article Type] Clinical Trial
Isolation of SARS-CoV-2 in Viral Cell Culture in Immunocompromised Patients With Persistently Positive RT-PCR ResultsRT-PCR 결과가 지속적으로 양성인 면역 저하 환자의 바이러스 세포 배양에서 SARS-CoV-2 분리Cellular and Infection Microbiology Published on 2022-02-022022-09-12 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome B cell Cell culture Chemotherapy collected Concentration coronavirus coronavirus disease COVID-19 Culture cultured cell cultures depleting determine Diagnosis Hematologic malignancy hosts Immunocompromised immunocompromised adult in viral initial Laboratory medicine leukemia lymphoma MOST Nasopharyngeal swab obinutuzumab one patient Patient patients plaque assays positive positive RT-PCR Positive test Prevent qRT-PCR Result risk factor rituximab RNA RT-PCR RT-PCR Ct SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 PCR SARS-CoV-2 RT-PCR SARS-CoV-2 transmission SARS-CoV-2 virus solid organ transplant therapy treated venetoclax Vero-hACE2-TMPRSS2 cells viral cell viral cell culture viral shedding viral titer virus zone [DOI] 10.3389/fcimb.2022.804175 PMC 바로가기 [Article Type] Cellular and Infection Microbiology
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic LeukemiaArticle Published on 2022-01-222022-10-31 Journal: Cancers [Category] COVID-19, [키워드] acute respiratory syndrome Administered advanced age Analysis Anti-CD20 antibody chronic chronic lymphocytic leukemia clinical experience CLL CLL patient Concentration coronavirus Course COVID-19 COVID-19 patient death died elevated lactate dehydrogenase Factor Hematological malignancy hemoglobin Hospitalization increased risk Infection inhibitor leukemia naïve outcome Patient performance status performed Platelet Prognosis required Retrospective study risk of death SARS-CoV-2 SARS-COV-2 infection significantly shorter simple survival the SARS-CoV-2 therapy treated Treatment tyrosine venetoclax with COVID-19 worldwide pandemic [DOI] 10.3390/cancers14030558 PMC 바로가기 [Article Type] Article
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia만성 림프구성 백혈병 환자에서 mRNA 항-COVID-19 백신 BNT162b2 및 mRNA-1273에 대한 체액 반응Article Published on 2022-01-112022-09-12 Journal: Blood advances [Category] SARS, 진단, [키워드] absence acute respiratory syndrome age anti-CD20 Antibody Response BNT162b2 CLL Combination coronavirus COVID-19 dose evaluate highest Humoral response immune response independent predictor individual inhibitor leukemia monoclonal antibody monotherapy mRNA mRNA-1273 mRNA-1273 vaccine multivariable analysis neutralizing monoclonal antibodies Older Patient post-dose Prophylactic provide receiving response rate risk SARS-CoV-2 second dose Seroconversion seronegative seronegative patient significantly higher single dose therapy treated Treatment treatment-naïve patient tyrosine vaccination Vaccine venetoclax [DOI] 10.1182/bloodadvances.2021006215 PMC 바로가기 [Article Type] Article
Vaccination for SARS-CoV-2 in Hematological Patients혈액학적 환자의 SARS-CoV-2 백신 접종Review Published on 2022-01-012022-09-11 Journal: Acta haematologica [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events Anti-CD20 antibodies antibody antigen receptor approach Better chimeric antigen receptor chronic lymphocytic leukemia chronic myeloid leukemia controlled trials coronavirus coronavirus disease Coronavirus disease 2019 correlation COVID-19 COVID-19 vaccine COVID-19 vaccines death demonstrated disease dose drugs effective Effectiveness evaluate excluded General population healthy subjects Hematological malignancies Hematological malignancy HM patient HM patients humoral Humoral response immune response Immunocompromised Immunocompromised patient Immunocompromised patients increased risk Infection kinase inhibitors leukemia Lymphocytic leukemia lymphoproliferative disorders mRNA vaccination mRNA vaccine Multiple myeloma Myeloma Non-Hodgkin Lymphoma non-randomized studies non-randomized study Patient patients patients with HM provided Randomized controlled trials reported respiratory response rate ruxolitinib Safe SARS-CoV-2 serology testing Seropositivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease T-cell T-cell Response T-cell responses therapy tyrosine tyrosine kinase inhibitors vaccination Vaccinations Vaccine venetoclax [DOI] 10.1159/000523753 PMC 바로가기 [Article Type] Review
Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration ProgramConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 유전자 메커니즘, 임상, 치료법, [키워드] acceleration AML Analysis Asymptomatic BMS board Celgene Chemotherapy clinical clinical study clinical trial Cohort cohort of patient concerning conducted Coronavirus disease 2019 cough COVID-19 COVID-19 infection cure death defined determine Diagnosis disease download education employment estimate exacerbated Exploratory analysis Fever figure Follow-up funding Hematological malignancy higher risk hospital immune response Immunosuppression incidence incidence of COVID-19 increasingly indicate Infection information intensity Intensive Jazz MDs median age myelodysplasia myeloid Non-COVID-19 Occurrence outcome pandemic Patient patient hospitalization patients patients treated Patients with cancer PCR test positive presenting symptom Program proportion Prospective provide receiving recruited reduce regimen regimens required Result resulting risk of COVID-19 risk of death SARS-CoV2 secondary severity speaker suffered Support table Takeda tested treated patients Treatment treatment arm treatment history vaccination venetoclax were infected [DOI] 10.1182/blood-2021-146061 [Article Type] Conference abstract
The Impact of COVID-19 on Acute Myeloid Leukemia (AML) Treatment Patterns in the United States: Retrospective Analysis of an Electronic Medical Records (EMR) DatabaseConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 치료법, [키워드] affected age AML Analysis Cancer change Characteristics Chemotherapy Cohort cohorts Community Comparisons consolidation COVID COVID-19 COVID-19 infection criteria current database defined diagnosed Diagnosis Donor dose download eligible EMR equity Estimated figure Follow-up follow-up period healthcare Hematologic malignancy high risk hospital hospitalizations HSCT Impact impacted induction Intensive Kaplan-Meier method lack less male median myeloid outcome pandemic Patient pattern Practitioner receive receiving Record reduce reducing regimens resource resources Retrospective analysis significantly significantly increased Standard of care Stem cell transplantation survival survival curve survival rate therapy time transplantation treated Treatment venetoclax was reduced was used were assessed [DOI] 10.1182/blood-2021-147979 [Article Type] Conference abstract
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort studyBNT162b2 COVID-19 mRNA 백신의 면역원성과 리투아니아 혈액암 환자의 초기 임상 결과: 국가 전향 코호트 연구Article Published on 2021-08-012022-09-12 Journal: The Lancet. Haematology [Category] MERS, SARS, 진단, [키워드] Abbott Abstract Adverse Affect age allogeneic HSCT anti-CD20 antibody Antibody Response Architect autologous Biobank blood sample BNT162b2 BNT162b2 vaccine circulating Clinical outcome clinically Cohort Community Concentration Course COVID-19 death dose doses Efficacy evaluate event genotyping haematological malignancy Health health-care healthy heterogeneous highest IgG IgG antibody immunogenicity Infection Intervention Lithuania main analysis malignancies malignancy material median Microparticle mRNA vaccination mRNA vaccine National negatively affected of BNT162b2 Older participant Patient patients with haematological Pfizer-BioNTech prospective cohort study questionnaire Registered response responses ruxolitinib SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 vaccine second dose serological response seronegative serum severe SARS-CoV-2 subgroup therapy translation treated Treatment tyrosine kinase inhibitor university untreated patient vaccination vaccine dose vaccine doses venetoclax Vilnius was done was used were assessed [DOI] 10.1016/S2352-3026(21)00169-1 PMC 바로가기 [Article Type] Article